Medical Genetics

Can Females Get Duchenne Muscular Dystrophy or Be Carriers?

At a Glance

Most females who inherit a DMD gene variant are carriers without obvious muscle weakness, but some develop muscle symptoms or heart disease. Genetic testing confirms carrier status, and every confirmed carrier should have an individualized plan for regular cardiac monitoring.

If your son has Duchenne muscular dystrophy (DMD), there is a possibility your daughter could carry the gene variant ^[1]. Most females with a DMD variant are asymptomatic carriers, but some develop muscle symptoms (known as “manifesting carriers”) ^[2]. Because the variant can silently affect the heart, all confirmed female carriers need an individualized cardiac monitoring plan ^[3]. While it is exceedingly rare, it is also possible for a female to have a full DMD presentation due to uncommon genetic circumstances, such as Turner syndrome ^[4].

How Duchenne is Inherited

DMD follows an X-linked recessive inheritance pattern ^[5]. The gene for dystrophin—the protein that protects muscles from damage—is located on the X chromosome.

Boys (XY) have one X chromosome. If they inherit a pathogenic (disease-causing) variant in the DMD gene, they do not have a backup copy and will develop the condition ^[5].
Girls (XX) have two X chromosomes. If they inherit the variant on one X chromosome, the healthy backup copy usually produces enough dystrophin to protect their muscles, making them a carrier ^[1].

It is important to know that having a son with DMD does not automatically mean you are a carrier. Sometimes, the variant is new (de novo) in the child ^[1]. However, if you are confirmed to be a carrier through genetic testing, each pregnancy has independent risks ^[5]:

Sons have a 50% chance of inheriting the variant and being affected.
Daughters have a 50% chance of inheriting the variant and being a carrier.

What is a “Manifesting Carrier”?

In every female cell, one X chromosome is naturally “turned off” so the body doesn’t double-dose on X-chromosome genes. This process, called X-chromosome inactivation, is usually random ^[6]. However, if a girl’s body turns off a disproportionate amount of the healthy X chromosomes (skewed X-inactivation), she may not make enough dystrophin and could develop muscle symptoms ^[6]. This is one possible reason a carrier might become symptomatic ^[7].

While significant muscle weakness is uncommon in female carriers ^[8], a manifesting carrier can experience:

Weakness in the hips, thighs, or shoulders ^[9]
Muscle pain, cramping, or calf enlargement ^[10]
Getting tired quickly during exercise or play ^[2]
High levels of creatine kinase (CK), an enzyme released into the blood when muscle is damaged, even if she has no outward weakness ^[2].

The Importance of Heart Monitoring

Even without obvious skeletal muscle symptoms, female carriers can develop heart issues like cardiomyopathy (weakening of the heart muscle) or irregular heartbeats ^[11]. Age of onset and risk can vary, but the absence of muscle weakness does not eliminate cardiac risk ^[12].

Recommended cardiac surveillance:

Routine Testing: Guidelines often recommend a baseline electrocardiogram (ECG) and echocardiogram (heart ultrasound) by the time carrier status is confirmed, or in late adolescence/early adulthood ^[13]. If normal, these are typically repeated every 3 to 5 years, or more frequently if abnormalities or symptoms are present ^[14].
Cardiac MRI (CMR): A cardiologist may recommend a cardiac MRI to look for early signs of scarring (fibrosis) in the heart muscle before pumping function is affected ^[15]. This is an individualized decision, not an automatic routine test for every child ^[16].
Treatment and Pregnancy: If heart changes are detected, a cardiologist may recommend treatments used for heart failure that can slow progression and reduce risk ^[17]. Additionally, confirmed carriers should have a cardiac review and genetic counseling before pregnancy, as pregnancy adds cardiovascular stress ^[3]^[18].

When to Seek Urgent Care:
Seek immediate medical attention if a carrier experiences fainting, new or worsening shortness of breath, unexplained swelling, chest pain, or sustained heart palpitations. Do not wait for a routine follow-up appointment.

What to Do Next: The Testing Sequence

Testing your daughter shouldn’t be the first step. The recommended process is ^[19]:

Identify the exact family variant by genetically testing your affected son.
Test the mother to see if she carries that exact genetic variant.
Consider testing the daughter. If the mother is a carrier, a genetic counselor can help you decide when and how to test your daughter ^[20].

A targeted genetic test is the definitive way to establish carrier status ^[19]. While a CK blood test can provide helpful clues, a normal CK level does not rule out being a carrier, and an elevated CK doesn’t definitively prove it ^[21].

Common questions in this guide

Can a girl or woman actually have Duchenne muscular dystrophy?

Most females who inherit a disease-causing DMD variant are carriers and have no obvious muscle symptoms. Some are manifesting carriers with weakness, fatigue, cramping, or elevated creatine kinase, and a full DMD presentation is very rare but can occur with unusual genetic circumstances such as Turner syndrome.

If a mother carries DMD, what are the chances for each child?

Each pregnancy is an independent event. A carrier mother has a 50% chance of passing the variant to a son, who would be expected to be affected, and a 50% chance of passing it to a daughter, who would usually be a carrier.

Why do female DMD carriers need heart checks if they feel well?

Female carriers can develop heart muscle weakness, called cardiomyopathy, or irregular heartbeats even when they have little or no skeletal muscle weakness. Care often includes a baseline ECG and echocardiogram, followed by repeat testing on a schedule set by the cardiologist. If results are normal, follow-up is often every 3 to 5 years, but timing is individualized.

What is the right way to test a daughter for DMD carrier status?

First, genetic testing should identify the exact DMD variant in the affected son. The mother can then be tested for that variant, and if she is a carrier, a genetic counselor can discuss targeted testing for the daughter. A creatine kinase blood test may provide clues, but a normal result does not rule out carrier status and an elevated result does not prove it.

Can female DMD carriers have muscle symptoms?

Yes. A female carrier may develop weakness in the hips, thighs, or shoulders, muscle pain or cramps, calf enlargement, or tiring quickly during exercise or play. This can happen when X-chromosome inactivation leaves too few active healthy copies of the DMD gene in muscle cells.

When should a female DMD carrier seek urgent care?

Seek immediate medical attention for fainting, new or worsening shortness of breath, unexplained swelling, chest pain, or sustained heart palpitations. These symptoms can signal a heart problem and should not wait for a routine appointment.

Key takeaways

Most females with one pathogenic DMD variant are carriers, but some develop muscle weakness, fatigue, cramps, or elevated creatine kinase.
Confirmed female carriers can develop cardiomyopathy or irregular heartbeats even without muscle symptoms, so individualized cardiac surveillance is important.
If a mother is confirmed as a carrier, each pregnancy independently gives sons a 50% chance of being affected and daughters a 50% chance of being carriers.
The usual testing sequence is to identify the affected son’s variant, test the mother, then discuss targeted testing for the daughter with a genetic counselor; creatine kinase testing cannot confirm or exclude carrier status.
Rarely, a female can have a full DMD presentation because of unusual genetic circumstances such as Turner syndrome.

References (21)

1
Incidence of Duchenne muscular dystrophy in the modern era; an Australian study.
Kariyawasam D, D'Silva A, Mowat D, et al.
European journal of human genetics : EJHG 2022; (30(12)):1398-1404 doi:10.1038/s41431-022-01138-2.
PMID: 35754057
2
Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy.
Liu C, Ma J, Lu Y, et al.
Neuromuscular disorders : NMD 2023; (33(10)):728-736 doi:10.1016/j.nmd.2023.08.008.
PMID: 37716855
3
Cardiac Involvement in Dystrophin-Deficient Females: Current Understanding and Implications for the Treatment of Dystrophinopathies.
Lim KRQ, Sheri N, Nguyen Q, Yokota T
Genes 2020; (11(7)) doi:10.3390/genes11070765.
PMID: 32650403
4
Co-incidence of Turner syndrome and Duchenne muscular dystrophy - an important problem for the clinician.
Kaczorowska E, Zimowski J, Cichoń-Kotek M, et al.
Developmental period medicine 2016; (20(4)):273-278.
PMID: 28216480
5
[Clinical practice guidelines for Duchenne muscular dystrophy].
Writing Group For Practice Guidelines For Diagnosis And Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese Medical Association , Tan H, Liang D, Wu L
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2020; (37(3)):258-262 doi:10.3760/cma.j.issn.1003-9406.2020.03.006.
PMID: 32128741
6
A female patient carrying a novel DMD mutation with non-random X-chromosome inactivation from a DMD family.
Sun MX, Jing M, Hua Y, et al.
BMC medical genomics 2024; (17(1)):46 doi:10.1186/s12920-024-01794-x.
PMID: 38303044
7
Duchenne muscular dystrophy coexisting with Down syndrome or Turner syndrome: Two case reports.
Pongsakornkullachart P, Chanvanichtrakool M, Dhachpramuk D, et al.
World journal of clinical pediatrics 2026; (15(2)):116726 doi:10.5409/wjcp.v15.i2.116726.
PMID: 42220943
8
Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status.
Miyagoe-Suzuki Y, Nishiyama T, Nakamura M, et al.
Stem cells international 2017; (2017()):7906843 doi:10.1155/2017/7906843.
PMID: 28491099
9
Genetic and Early Clinical Manifestations of Females Heterozygous for Duchenne/Becker Muscular Dystrophy.
Papa R, Madia F, Bartolomeo D, et al.
Pediatric neurology 2016; (55()):58-63.
PMID: 26718981
10
The Expanding Spectrum of Dystrophinopathies: HyperCKemia to Manifest Female Carriers.
Suthar R, Kesavan S, Sharawat IK, et al.
Journal of pediatric neurosciences 2021; (16(3)):206-211 doi:10.4103/jpn.JPN_89_20.
PMID: 36160614
11
Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: a comparative cardiovascular magnetic resonance study.
Florian A, Rösch S, Bietenbeck M, et al.
European heart journal. Cardiovascular Imaging 2016; (17(3)):326-33 doi:10.1093/ehjci/jev161.
PMID: 26113120
12
Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging.
Lang SM, Shugh S, Mazur W, et al.
Pediatric cardiology 2015; (36(7)):1495-501 doi:10.1007/s00246-015-1192-7.
PMID: 25976773
13
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.
Birnkrant DJ, Bushby K, Bann CM, et al.
The Lancet. Neurology 2018; (17(4)):347-361 doi:10.1016/S1474-4422(18)30025-5.
PMID: 29395990
14
Longitudinal changes in cardiac function, volumes and fibrosis in a prospective cohort of female Duchenne and Becker muscular dystrophy carriers.
Ledingham L, Conroy S, Kanwar K, et al.
International journal of cardiology 2026; (457()):134551 doi:10.1016/j.ijcard.2026.134551.
PMID: 42106074
15
Cardiac MRI in cardiac dystrophinopathy: recommendations on imaging.
McDiarmid A, Augustine D, Coats C, et al.
Open heart 2026; (13(1)) doi:10.1136/openhrt-2026-004037.
PMID: 42161423
16
Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers.
Wexberg P, Avanzini M, Mascherbauer J, et al.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2016; (18(1)):61 doi:10.1186/s12968-016-0281-y.
PMID: 27660108
17
[Cardiac involvement in dystrophinopathies].
Wahbi K
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2015; (22(12 Suppl 1)):12S37-41.
PMID: 26773585
18
Successful Pregnancy Outcome With Preconception Care in a Symptomatic Carrier of Duchenne Muscular Dystrophy: Case Report and Literature Review.
Kinugawa M, Ichinose M, Matsui H, et al.
American journal of medical genetics. Part A 2025; (197(3)):e63926 doi:10.1002/ajmg.a.63926.
PMID: 39482265
19
Molecular genetic testing and diagnosis strategies for dystrophinopathies in the era of next generation sequencing.
Zhang K, Yang X, Lin G, et al.
Clinica chimica acta; international journal of clinical chemistry 2019; (491()):66-73 doi:10.1016/j.cca.2019.01.014.
PMID: 30660698
20
Genetic counseling, prenatal diagnosis and newborn screening in Duchenne muscular dystrophy.
Leturcq F, Verebi C, Nectoux J
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2025; (32(7S1)):7S64-7S69 doi:10.1016/S0929-693X(25)00256-8.
PMID: 41391914
21
Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing.
Han S, Xu H, Zheng J, et al.
BioMed research international 2020; (2020()):8396429 doi:10.1155/2020/8396429.
PMID: 33029525

This page is for informational purposes only and does not constitute medical advice. A genetic counselor and cardiologist can interpret your family’s results and create an individualized monitoring plan.